7月16日 - ** Regenxbio（RGNX.O）股价在盘后交易中下跌14.1%，至9.62美元，因该公司计划进行股权融资
** 总部位于马里兰州罗克维尔的生物技术公司 (link) 宣布将进行1亿美元的股票发行
** 摩根士丹利、摩根大通、Leerink和瑞穗担任联合簿记管理人
** 根据招股说明书，RGNX计划将本次发行所得净收益用于一般用途，包括资助临床试验、资本支出、营运资金、候选产品管线的开发以及偿还债务等 (link)
** 上月，RGNX表示美国食品药品监督管理局（FDA）撤销了对该公司罕见病基因疗法Navsunli的拒绝决定 (link)，支持其加速批准申请；据称该公司已从合作伙伴艾伯维（AbbVie） ABBV.N 就其眼科疾病药物获得1亿美元里程碑付款 (link)
** RGNX股价周四收跌8.7%，报11.20美元。该股过去一个月累计上涨62%，但年初至今仍下跌22%
** 该公司市值约为5.8亿美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.